ASSOCIATED PRESS
Vabysmo (faricimab-svoa) is a vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) inhibitor indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO). ...
A new study, being presented at the 128th annual meeting of the American Academy of Ophthalmology in Chicago, reveals that patients receiving monthly treatment with the investigational drug ANX007 reduced their risk of vision loss by 72 percent. The data also showed that signi...
a disease that affects the central vision. This drug helps preserve vision and limit progression of wet AMD to legal blindness. Another such drug, Retaane, is also up for FDA-approval. Macular degeneration is deterioration or breakdown of the macula, a small area in the retina at the back ...
Macugen (pegaptanib), the only approved aptamer drug, was approved in 2004. Macugen is a DNA oligo modified with a long polyethylene glycol chain (PEGylation). It binds to and acts as a vascular endothelial growth factor (VEGF) antagonist for the treatment of wet aged-related macular ...
In a news release, the company indicated the data further advance the depth of clinical and real-world evidence supporting the use of faricimab (Vabysmo), the first and only bispecific antibody for the eye, for the treatment of neovascular or ...
Ranibizumab launches new era for wet AMD. (cover story)The article reports that the U.S. Food and Drug Administration has approved ranibizumab injection 0.5 mg for treating patients with neovascular age-related macular degeneration. Clinical trials have shown that ranibizumab has unprecedented activity...
Data from a phase 1 study of the efficacy of RG7716 showed patients who had been diagnosed with wet AMD for 2 or more years had a seven to eight letter improvement in vision after being treated with th...
in treating patients with the wet form of macular degeneration.24Lacking the Fc region, a Fab can be produced in an economic expression system (e.g., yeast) and prevent Fc-related adverse effects in vivo. Predictably, a Fab has a shorter half-life due to the lack of FcRn-mediated recycl...
potentially any disease target in clinical studies and to thereby treat disease in a new manner. In the near future, the ongoing clinical trials with siRNAs for macular degeneration and RSV may reveal the exciting potential of RNAi therapeutics as the next major class of drug molecules....